Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
CAMBRIDGE, Mass., Feb. 22, 2018 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter and full-year 2017 financial results, business highlights and 2018 financial guidance.
| What: | Vericel Corporation Fourth-Quarter 2017 Earnings Call | |
| When: | Monday, March 5, 2018 at 8:30am (EST) | |
| Where: | http://investors.vcel.com/events-presentations | |
| How: | The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events-presentations. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. |
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation fourth-quarter 2017 earnings call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events-presentations until March 5, 2019. A replay of the call will also be available until 11:30am (EST) on March 10, 2018 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 4899311.
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
The Trout Group
[email protected]
+1 (646) 378-2947
Lee Stern
The Trout Group
[email protected]
+1 (646) 378-2922
